BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34007173)

  • 1. A Dual pH-Responsive DOX-Encapsulated Liposome Combined with Glucose Administration Enhanced Therapeutic Efficacy of Chemotherapy for Cancer.
    Zhai L; Luo C; Gao H; Du S; Shi J; Wang F
    Int J Nanomedicine; 2021; 16():3185-3199. PubMed ID: 34007173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
    Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
    J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy.
    Jiang Y; Zhou Y; Zhang CY; Fang T
    Int J Nanomedicine; 2020; 15():3319-3331. PubMed ID: 32494132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery.
    Xu H; Hu M; Yu X; Li Y; Fu Y; Zhou X; Zhang D; Li J
    Eur J Pharm Biopharm; 2015 Apr; 91():66-74. PubMed ID: 25660909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
    Ling L; Ismail M; Du Y; Yao C; Li X
    Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free Adriamycin-Loaded pH/Reduction Dual-Responsive Hyaluronic Acid-Adriamycin Prodrug Micelles for Efficient Cancer Therapy.
    Yin T; Wang Y; Chu X; Fu Y; Wang L; Zhou J; Tang X; Liu J; Huo M
    ACS Appl Mater Interfaces; 2018 Oct; 10(42):35693-35704. PubMed ID: 30259743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pH-Sensitive, Long-Circulating Liposomes as an Alternative Tool to Deliver Doxorubicin into Tumors: a Feasibility Animal Study.
    Silva JO; Fernandes RS; Lopes SC; Cardoso VN; Leite EA; Cassali GD; Marzola MC; Rubello D; Oliveira MC; de Barros AL
    Mol Imaging Biol; 2016 Dec; 18(6):898-904. PubMed ID: 27172938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model.
    de Oliveira Silva J; Fernandes RS; Ramos Oda CM; Ferreira TH; Machado Botelho AF; Martins Melo M; de Miranda MC; Assis Gomes D; Dantas Cassali G; Townsend DM; Rubello D; Oliveira MC; de Barros ALB
    Biomed Pharmacother; 2019 Oct; 118():109323. PubMed ID: 31400669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming.
    Tan X; Fang Y; Ren Y; Li Y; Wu P; Yang X; Liu W
    Int J Nanomedicine; 2019; 14():1255-1268. PubMed ID: 30863058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
    Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
    Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
    Zhang Q; Tang J; Fu L; Ran R; Liu Y; Yuan M; He Q
    Biomaterials; 2013 Oct; 34(32):7980-93. PubMed ID: 23891517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer.
    Yi H; Lu W; Liu F; Zhang G; Xie F; Liu W; Wang L; Zhou W; Cheng Z
    J Nanobiotechnology; 2021 May; 19(1):134. PubMed ID: 33975609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
    Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
    Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular structural transformation regulated dynamic disordering of supramolecular vesicles as pH-responsive drug release systems.
    Liu Y; Gao FP; Zhang D; Fan YS; Chen XG; Wang H
    J Control Release; 2014 Jan; 173():140-7. PubMed ID: 24188958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid liposome/metal-organic framework as a promising dual-responsive nanocarriers for anticancer drug delivery.
    Karami A; Ahmed A; Sabouni R; Husseini GA; Sharabati MA; AlSawaftah N; Paul V
    Colloids Surf B Biointerfaces; 2022 Sep; 217():112599. PubMed ID: 35714509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.